Logo

Proteome and Egenix to Develop Semen-Screening Diagnostic for Prostate Cancer

Mar 07, 2006

NEW YORK, March 7 (GenomeWeb News) - Proteome and Egenix will co-develop a semen-based diagnostic kit for prostate cancer, Proteome said today.

 

The non-invasive test will be based on the human carcinoma antigen.

 

Under the agreement, Egenix will fund research to optimize the detection of HCA in semen of prostate cancer patients. The companies will then share the rights for further development and commercialization of the test.

 

Egenix estimated a potential US market size for the HCA test of up to $1.5 billion, according to a statement.

 

"We initially wondered if there would be social or cultural objections to a test that requires the patient to provide an ejaculate specimen," said Egenix president Jedd Levine. "But it's common to look in organ secretions for signs of cancer in that organ and ... most men would willingly provide a semen specimen to potentially avoid a painful needle biopsy."

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.